COSTA MESA, CA / ACCESSWIRE / December 20, 2016 / NEMUS Bioscience, Inc. (OTCQB: NMUS) announced it has signed a definitive license agreement for rights to Teewinot Life Sciences Corp.’s patented biosynthetic technology to produce NEMUS’ proprietary cannabinoid molecules.
“Nemus is anticipating an era of hypergrowth in the pharmaceuticalized cannabinoid space and we believe that the biosynthetic technology that Teewinot has developed fits with our industry-disruptive approach to this therapeutic market,” commented Brian Murphy, M.D., M.B.A., CEO and Chief Medical Officer of Nemus. “We believe that the use of standard cannabinoid molecules like tetrahydrocannabinol (THC) and cannabidiol (CBD) can be improved upon using re-engineered proprietary forms of the molecules to enhance physicochemical characteristics, resulting in improved activity and safety in a business model not solely dependent on orphan drug applications. We anticipate that the biosynthetic technology being advanced by Teewinot will provide API that is more cost-effective to
... read more at: http://www.baystreet.ca/viewarticle.aspx?id=451385